Austin, Texas 11/19/2007 11:59:48 PM
Speak with other shareholders about: (OTCBB: AVEE), (NASD: MCEL), (NASD: DSCO), (OTCBB: GTRY)
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the Chat Live button at the top.
----------------------------------------------------------
Chat real-time with other investors about this AVEE news release,
by clicking this link: http://www.stockwire.com/AVEE
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=AVEE
ADVANT-E CORPORATION (OTCBB: AVEE) "Up 13.64% in morning trading"
Advant-e Corporation, through its wholly owned subsidiary, Edict Systems, Inc., provides business-to-business (B2B) electronic commerce (e-commerce) products and services in the United States and Canada. It develops, markets, and supports electronic data interchange (EDI) and e-commerce software products and services that enable its customers to send and receive business documents electronically. The company also provides consultative services for its customers, wherein it acts as a liaison between the buyers and their suppliers. Its products and services include Web EDI, a Web-based electronic data interchange document processing system that allows suppliers to conduct electronic commerce with grocery and other retailers, automotive manufacturers, and other buying organizations; EnterpriseEC, an Internet-based B2B e-commerce network service; and Value-Added Applications, which enable customer to monitor their e-commerce activities via a hosted business rules engine. Advant-e Corporation also provides hosted data translation services that allow companies to integrate EDI date with their in-house systems. The company was founded in 1990 and is based in Dayton, Ohio.
AVEE News:
November 19 - Advant-e Corporation Announces Third Quarter 2007 Results
Company Reports 59% Increase in Revenue and 45% Net Income Growth over Q3 2006
Share Repurchase Program - The Company purchased 60,000 shares at $1.25 as part of the share repurchase program.
Jason K. Wadzinski, Chairman and Chief Executive Officer, remarked, "The third quarter of 2007 was highlighted by our recent acquisition of Merkur Group, Inc., which accounted for 28% of our revenue and contributed to our profitability for the quarter. We are currently working on several opportunities to increase revenue for both Edict and Merkur by leveraging the strengths and product/service offerings of each company."
----------------------------------------------------------
Chat real-time with other investors about this MCEL news release,
by clicking this link: http://www.stockwire.com/MCEL
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=MCEL
MILLENNIUM CELL INC (NASD: MCEL) "Up 15.69% in morning trading"
Millennium Cell, Inc. develops hydrogen batteries for use primarily in portable electronic devices for the military, medical, industrial, and consumer markets. The hydrogen batteries comprise a fuel cell and hydrogen fuel cartridge technology. The fuel blends used in the hydrogen battery technology are comprised of a combination of water, sodium borohydride, and other chemicals. The hydrogen produced by its hydrogen fuel cartridge technology is converted into electricity by a fuel cell. The company develops the technology in partnership with corporate and government entities. It also licenses its fuel cartridge technology to fuel cell manufacturers, original equipment manufacturers, and other product-focused entities. The company has a strategic relationship with The Dow Chemical Company to collaborate on the design, development, and commercialization of proton exchange membrane fuel cell power systems and compatible Hydrogen on Demand fuel cartridges for use in portable electronic devices; and with Horizon Fuel Cell Technologies Pte, Ltd. focused on the commercialization of fuel cell based power products. Millennium Cell was founded in 1998 and is based in Eatontown, New Jersey.
MCEL News:
November 16 - Fuel Cartridges Authorized for International Air Transport
Clears Path for Millennium Cell's Hydrogen on Demand(R) and Solid State HOD(TM) Cartridges on Aircraft
Millennium Cell Inc. (NASD: MCEL) announced that the International Civil Aviation Organization ("ICAO") has created new regulations that permit the transportation in carry-on baggage on passenger aircraft of micro fuel cell systems which utilize fuel cartridges including the sodium borohydride fuels being developed by Millennium Cell to power electronic devices. Fuels covered include fuel for HOD systems and next-generation Solid State HOD systems. The Company expects these ICAO model regulations, which are developed by international consensus, to become effective world-wide by January of 2009.
----------------------------------------------------------
Chat real-time with other investors about this DSCO news release,
by clicking this link: http://www.stockwire.com/DSCO
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=DSCO
DISCOVERY LABS (NASD: DSCO) "Up 11.89% in morning trading"
Discovery Laboratories, Inc., together with its subsidiaries, operates as a biotechnology company that develops proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory disorders and diseases. Its products include Surfaxin (lucinactant), which is used for the prevention of respiratory distress syndrome in premature infants, as well as for the prevention of bronchopulmonary dysplasia in premature infants; and Aerosurf, which is used for the prevention and treatment of respiratory failure in infants. The company also provides its products for the treatment of acute respiratory failure, cystic fibrosis, acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disorder, asthma, and other debilitating respiratory conditions. It has strategic alliances with Chrysalis Technologies to develop and commercialize aerosolized SRT for various respiratory conditions, such as acute lung injury, neonatal respiratory failure, chronic obstructive respiratory disease, and asthma; and Laboratorios del Dr. Esteve, S.A. to develop, market, and sell Surfaxin in Europe, Central and South America, and Mexico. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
DSCO News:
November 19 - Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA
Discovery Laboratories, Inc. (NASD: DSCO) announced that the U.S. Food and Drug Administration (FDA) has accepted Discovery Labs' submission of November 1, 2007 as a complete response to the April 2006 Approvable Letter for Surfaxin(r) (lucinactant), for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA has established May 1, 2008 as its target date to complete its review of the Surfaxin New Drug Application (NDA).
Surfaxin is a precision-engineered version of natural human lung surfactant and contains Discovery Labs' novel KL-4 peptide. Surfaxin, administered as a liquid-instillate, represents a potential alternative to the commercially available animal-derived surfactants. Data from Discovery Labs' pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled analysis of the Phase 3 studies, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics. In addition, top-line results from Discovery Labs' Phase 2 clinical trial for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) suggested that infants treated with up to five incremental standard doses of Surfaxin tended to have a lower incidence of death or BPD, a higher survival rate through 36 weeks post-menstrual age, and fewer days on mechanical ventilation. Discovery Labs recently initiated a Phase 2 clinical trial evaluating the use of Surfaxin in children up to two years of age suffering from Acute Respiratory Failure (ARF). This new trial will explore the expanded application of surfactant therapy to pediatric critical care medicine.
----------------------------------------------------------
Chat real-time with other investors about this GTRY news release,
by clicking this link: http://www.stockwire.com/GTRY
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=GTRY
GETTING READY CORPORATION (OTCBB: GTRY) "Up 9.52% in morning trading"
Getting Ready Corporation is a public shell company. It intends to effect a merger, acquisition, or other business combination with an operating company by using a combination of common stock, cash on hand, or other funding sources. The company was founded in 2002 and is based in Miami, Florida.
GTRY News:
November 19 - Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement Winston Laboratories, Inc., a specialty pharmaceutical company engaged in the discovery and development of products for pain management, and Getting Ready Corporation (OTCBB: GTRY), a publicly-traded company with no active operations, have signed a merger agreement that will bring the two companies under one umbrella. The combined company will be renamed Winston Pharmaceuticals, Inc., and will be headquartered in Vernon Hills, Illinois. The merger is expected to close in the second quarter of 2008, and shortly thereafter, the company intends to apply to have its shares listed on the American Stock Exchange (AMEX).
Mr. Halpryn stated that Winston's scientific and management teams have extensive experience in clinical development for pain indications. Mr. Halpryn also said that he is pleased that Getting Ready was able to enter into this merger agreement within a year of the change of control of Getting Ready, and he looks forward to serving as a member of the board of directors of the combined company following the closing.
About Winston Laboratories
Winston Laboratories focuses on major pain indications as well as on niche markets, where there is still significant unmet need for pain management options with improved efficacy, safety, and tolerability profiles. Winston's product candidates span a range of pain indications, including episodic cluster headache, chronic daily headache, osteoarthritis, neuropathic pain, cancer pain and post-operative pain.
Winston Laboratories' flagship compound is civamide, a TRPV-1 (transient receptor potential vanilloid-1) receptor modulator, which we believe provides exceptionally long-lasting analgesic activity. A single oral dose of civamide, for example, provides effective analgesia for at least 7 days in a variety of animal pain models. Winston is engaged in late-stage development of civamide for various pain indications, and expects to submit its first marketing authorization applications for a topical formulation in North America and Europe for relief of osteoarthritis pain during the first quarter of 2008.
About Civamide
Civamide (cis-8-methyl-N-vanillyl-6-nonenamide) is a patented, synthetically produced agent that binds to the TRPV-1 receptor, and, in this fashion, selectively depresses the activity of the type-C pain fibers. Civamide causes an initial release of the neuropeptides, substance P (SP) and calcitonin-gene related peptide (CGRP). Pain transmission is then diminished by the subsequent depletion of SP and CGRP from the neuron, coupled with suppression of the synthesis and transport of neuropeptides along the neuron.
--------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the National Association of Securities Dealers (NASDAQ) at www.NASDAQ.com. The NASDAQ has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We often receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares into the open market.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
